Skip to content

1 The World Drug Market for Psoriasis in 2012: Biologic Drugs Dominate In Terms of Revenue3

1 The World Drug Market for Psoriasis in 2012: Biologic Drugs Dominate In Terms of Revenue3 1

Visiongain’s new report gives you revenue predictions from 2013, helping you stay ahead. Psoriasis Treatment: World Drug Market 2013-2023. Psoriasis drugs – this new study shows you R&D, opportunities, and potential revenues. Biologics (biological drugs) Topical treatments Small-molecule systemic agents. 3.5.1 Biologic Drugs for Psoriasis: Revenue Forecast, 2013-20233. Markets in 2012: The US Dominates the Psoriasis Drug Market5. 7.2 AbbVie, Previously Abbott, Leads the Psoriasis Drug Market in Terms of Revenue7. The high growth rate in growth factor market and Amgen’s dominant position (Fig. Figure 2: Top ten categories of biologic drugs in terms of US sales in 2006. MAbs represent the second largest category in the US biotech drug market with sales of 11.

1 The World Drug Market for Psoriasis in 2012: Biologic Drugs Dominate In Terms of Revenue3 2Some definitions seek to specify alternative medicine in terms of its social and political marginality to mainstream healthcare. In respect of taxation in the US, the Internal Revenue Service has discriminated in favour of medical expenses for acupuncture and chiropractic (and others including Christian Science practitioners) but against homeopathy and the use of non-prescription required medicine. Now, here’s the full list of new drugs approved by the FDA in 2015, in chronological order. And in the patent cliff environment that has persisted for several years now, it takes blockbuster gains to make a big difference for the Big Pharma companies that dominate the industry. GlaxoSmithKline (GSK), meanwhile, managed one new drug OK: Nucala. Enbrel is one of the top ten drugs in the U.S. by sales, garnering the pharmaceutical giants who co-market the drug, Amgen and Pfizer, billions of dollars in revenue annually. People take Enbrel for inflammatory conditions like rheumatoid arthritis and psoriasis, at prices of tens of thousands of dollars per year. Enbrel is a biotech drug, or as the industry calls it, a biologic.

One-quarter of surveyed drug companies expected to see mobile app spending grow. Branded Biologics Sales Will Grow The growing dependence on biologics to provide significant benefits in the effective treatment of chronic diseases such as rheumatoid arthritis, psoriasis, cancer, Crohn’s disease, and similar conditions has resulted in the continued increase in sales, generating more than 128 billion in 2012 alone, according to GlobalData. States in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a CAGR of 8 over 2012-2018, beating the U. According to a survey conducted by market research firm Decision Resources, 72 percent of the dermatologists interviewed said that they are willing to prescribe this therapy to their patients once it becomes available. Stelara from Johnson and Johnson (NYSE:JNJ) is a biological drug. 08 billion worth of drugs globally, a 44 percent increase from the year before. Psoriasis is a long-term skin problem that causes skin cells to grow too quickly, resulting in thick, white, silvery, or red patches of skin. 18 billion in annual revenue, owning a strong portfolio of drugs such as Humira, AndroGel, Lupron, and Synagis. Humira is also approved in more than 60 markets in the world.

Alternative Medicine

Di-glyceride & derivatives dominate the market in terms of volume.

Adherence Can Lead To Healthcare Savings